Yu-Wan Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yu-Wan Yang has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Audrey Yang
Novartis (Taiwan) Co., Ltd., Taipei, Taiwan
1 shared publication- Chaur-Jong Hu
Dementia Center, Shuang Ho Hospital and Department of Neurology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
1 shared publication Chia-Chun Wang
Artificial Intelligence Center, China Medical University Hospital, Taichung, 40447, Taiwan
1 shared publication- Chin-I. Chen
Department of Neurology, Wan Fang Hospital, Taipei, Taiwan
1 shared publication - Chiung-Chih Chang
Department of Neurology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan
1 shared publication Chon-Haw Tsai
Department of Neurology, China Medical University Hospital, Taichung, 40447, Taiwan; School of Medicine, College of Medicine, China Medical University, Taichung, 40402, Taiwan; Neuroscience Laboratory, Department of Neurology, China Medical University Hospital, Taichung, 40447, Taiwan; Neuroscience and Brain Disease Center, College of Medicine, China Medical University, 40402, Taichung, Taiwan
1 shared publication
Latest Publications
- 17 May 2024
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 176, 108621
Comparative analysis of machine learning algorithms for Alzheimer's disease classification using EEG signals and genetic information
- 17 May 2024
- Published by Elsevier in Computers in Biology and Medicine
- Vol. 176, 108621
Comparative analysis of machine learning algorithms for Alzheimer's disease classification using EEG signals and genetic information
- Open Access
- 10 September 2021
- Published by Springer Nature in Advances in Therapy
- Vol. 38 (10) , 5286-5301
Effectiveness of the 10 cm2 Rivastigmine Patch in Taiwanese Patients with Mild-to-Moderate Alzheimer’s Dementia: A 48-Week Real-World Observational Study
Introduction The current study aimed to provide data on the effectiveness of the 10 cm2 rivastigmine patch in patients with Alzheimer’s disease (AD) in a real-world setting in Taiwan. Methods This was a 48-week, single-arm, open-label, observational, and post-marketing study conducted across seven centers in Taiwan between May 5, 2016 and July 10, 2017. Eligible patients (aged 55–95 years) treated with the 10 cm2rivastigmine patch were enrolled based on physicians’ judgment and according to the Taiwan reimbursement criteria of the drug. Data were prospectively collected at Week 0 (baseline), Week 24, and Week 48. The primary endpoint was the change in the cognitive assessment screening instrument (CASI) scores at Week 48 versus baseline. The changes from baseline in clinical dementia rating (CDR), mini-mental state examination (MMSE), and neuropsychiatric inventory (NPI) scores were evaluated, as were treatment persistence and the safety profile. Results Of the 285 eligible patients [full analysis set (FAS)], 216 (75.8%) completed the study protocol while 180 (63.2%) persisted on the 10 cm2 rivastigmine patch for the full 48 weeks. At baseline, 89.8% of patients had a CDR score of 0.5 or 1, while the change in CDR score at Week 48 was not significant. In the FAS, both the CASI and MMSE scores had numerical improvement at Week 24 but declined by 2.1 and 0.4 points, respectively, at Week 48 (p = 0.005 and p = 0.022). The increment in NPI scores was not significant. The most common drug-related adverse events (AEs) were pruritus (11.2%), nausea (3.5%), rash (3.2%), and vomiting (2.8%). Conclusions The use of the 10 cm2 rivastigmine patch in the mild stage of AD maintained cognitive function at Week 24 and neuropsychiatric function at Week 48. The treatment persistency and safety profile support the clinical tolerability of the rivastigmine patch in the management of mild-to-moderate AD in Taiwan.
- 10 September 2021
- Published by Springer Nature in Advances in Therapy
- Vol. 38 (10) , 5286-5301
Open AccessEffectiveness of the 10 cm2 Rivastigmine Patch in Taiwanese Patients with Mild-to-Moderate Alzheimer’s Dementia: A 48-Week Real-World Observational Study
Introduction The current study aimed to provide data on the effectiveness of the 10 cm2 rivastigmine patch in patients with Alzheimer’s disease (AD) in a real-world setting in Taiwan. Methods This was a 48-week, single-arm, open-label, observational, and post-marketing study conducted across seven centers in Taiwan between May 5, 2016 and July 10, 2017. Eligible patients (aged 55–95 years) treated with the 10 cm2rivastigmine patch were enrolled based on physicians’ judgment and according to the Taiwan reimbursement criteria of the drug. Data were prospectively collected at Week 0 (baseline), Week 24, and Week 48. The primary endpoint was the change in the cognitive assessment screening instrument (CASI) scores at Week 48 versus baseline. The changes from baseline in clinical dementia rating (CDR), mini-mental state examination (MMSE), and neuropsychiatric inventory (NPI) scores were evaluated, as were treatment persistence and the safety profile. Results Of the 285 eligible patients [full analysis set (FAS)], 216 (75.8%) completed the study protocol while 180 (63.2%) persisted on the 10 cm2 rivastigmine patch for the full 48 weeks. At baseline, 89.8% of patients had a CDR score of 0.5 or 1, while the change in CDR score at Week 48 was not significant. In the FAS, both the CASI and MMSE scores had numerical improvement at Week 24 but declined by 2.1 and 0.4 points, respectively, at Week 48 (p = 0.005 and p = 0.022). The increment in NPI scores was not significant. The most common drug-related adverse events (AEs) were pruritus (11.2%), nausea (3.5%), rash (3.2%), and vomiting (2.8%). Conclusions The use of the 10 cm2 rivastigmine patch in the mild stage of AD maintained cognitive function at Week 24 and neuropsychiatric function at Week 48. The treatment persistency and safety profile support the clinical tolerability of the rivastigmine patch in the management of mild-to-moderate AD in Taiwan.